Hutch News

Hutch News

Stories tagged 'Ovarian Cancer'

Endometriosis linked to childhood abuse

New Fred Hutch collaboration highlights yet another poor health outcome associated with adverse childhood experiences

July 17, 2018 | By Diane Mapes / Fred Hutch News Service

A new study led by Fred Hutch epidemiologist Dr. Holly Harris found an association between childhood abuse and endometriosis. Women reporting severe to chronic abuse had a 79 percent higher risk of developing the condition.

View story >


Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal

T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers

April 16, 2018 | By Rachel Tompa / Fred Hutch News Service

In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 25, 2018

Dr. Goldie Lui receives grant from Ovarian Cancer Research Fund Alliance; Fred Hutch, SCCA receive ‘Good Neighbor’ and ‘Nonprofit of the Year’ awards from South Lake Union Chamber.

View story >


The latest in gynecological cancer research from the Pacific Northwest

Inaugural Northwest Gynecological Cancer Symposium brings together scientists studying ovarian, cervical and endometrial cancers

Dec. 6, 2017 | By Rachel Tompa / Fred Hutch News Service

Monday, cancer researchers from around the Pacific Northwest gathered at Fred Hutchinson Cancer Research Center to discuss their latest efforts to better prevent, detect and treat cancers of the female reproductive tract in the inaugural Northwest Gynecological Cancer Symposium.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


How cancer fools healthy neighboring cells

‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients

July 18, 2017 | By Rachel Tompa / Fred Hutch News Service

Like tiny con men, cancer cells have many tricks to fool healthy cells into helping them. Research into the "tumor microenvironment" is uncovering new avenues for treatment.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.